The lawsuit alleges McNeil illegally promoted its medications by falsely claiming they were manufactured in compliance with federal regulations, according to the report.
McNeil recalled millions of drugs manufactured between 2009 and 2011 at its Fort Washington, Penn.-based plant, following reports of abnormal odors and foreign particles in its liquid medications. The drugs were sold under the following brand names: Tylenol, Motrin, Benadryl, St. Joseph Aspirin, Sudafed, Pepcid, Mylanta, Rolaids and Zyrtec.
In a Wednesday statement, Johnson & Johnson said it was “pleased” to finalize the settlement, reports Chicago Tribune. The company noted the recalls were voluntary and said McNeil-PPC admits no wrongdoing through the settlement, according to the report.
More articles on supply chain:
Biogen offshoot to acquire rare disease biotech for $400M: 4 things to know
Why FDA’s newest approval paves the way for precision medicine
Supply chain tip of the day: How pharmacy can drive revenue for a health system post-merger
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
